Page 63 - AN-3-3

Advanced Neurology HS-proteoglycans and brain function

Voest EE, Gebbink MF. Recombinant endostatin forms amyloid aggregation in Alzheimer’s disease: An attractive target for
fibrils that bind and are cytotoxic to murine neuroblastoma the development of novel therapeutic agents. Eur J Med
cells in vitro. FEBS Lett. 2003;539(1-3):149-155. Chem. 2017;139:153-167.
doi: 10.1016/s0014-5793(03)00218-7 doi: 10.1016/j.ejmech.2017.07.070
67. Van Horssen J, Wilhelmus MM, Heljasvaara R, et al. Collagen 77. Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting
XVIII: A novel heparan sulfate proteoglycan associated Alpha-synuclein as a therapy for Parkinson’s disease. Front
with vascular amyloid depositions and senile plaques in Mol Neurosci. 2019;12:299.
Alzheimer’s disease brains. Brain Pathol. 2002;12(4):456-462. doi: 10.3389/fnmol.2019.00299
doi: 10.1111/j.1750-3639.2002.tb00462.x 78. Vidović M, Rikalovic MG. Alpha-synuclein aggregation
68. Tanase C, Enciu AM, Codrici E, et al. Fatty acids, CD36, pathway in Parkinson’s disease: Current status and novel
thrombospondin-1, and CD47 in glioblastoma: Together therapeutic approaches. Cells. 2022;11(11):1732.
and/or separately? Int J Mol Sci. 2022;23(2):604. doi: 10.3390/cells11111732
doi: 10.3390/ijms23020604 79. Pan L, Li C, Meng L, et al. Tau accelerates α-synuclein
69. Cuttler K, Hassan M, Carr J, Cloete R, Bardien S. aggregation and spreading in Parkinson’s disease. Brain.
Emerging evidence implicating a role for neurexins in 2022;145(10):3454-3471.
neurodegenerative and neuropsychiatric disorders. Open doi: 10.1093/brain/awac171
Biol. 2021;11(10):210091.
80. Javed H, Nagoor Meeran MF, Azimullah S, Adem A,
doi: 10.1098/rsob.210091 Sadek B, Ojha SK. Plant extracts and phytochemicals
70. Hudák A, Letoha A, Vizler C, Letoha T. Syndecan-3 as targeting α-synuclein aggregation in Parkinson’s disease
a novel biomarker in Alzheimer’s disease. Int J Mol Sci. models. Front Pharmacol. 2019;9:1555.
2022;23(6):3407. doi: 10.3389/fphar.2018.01555
doi: 10.3390/ijms23063407 81. De Andrade Teles RB, Diniz TC, Costa Pinto TC, et al.
71. Saroja SR, Gorbachev K, Julia T, Goate AM, Pereira AC. Flavonoids as therapeutic agents in Alzheimer’s and
Astrocyte-secreted glypican-4 drives APOE4-dependent Parkinson’s diseases: A systematic review of preclinical
tau hyperphosphorylation. Proc Natl Acad Sci U S A. evidences. Oxid Med Cell Longev. 2018;2018:7043213.
2022;119(34):e2108870119. doi: 10.1155/2018/7043213
doi: 10.1073/pnas.2108870119 82. Cryan JF, O’Riordan KJ, Cowan CSM, et al. The microbiota-
72. García-Prieto IID, Lopez-Martín S, Albert J, et al. Mutations gut-brain axis. Physiol Rev. 2019;99(4):1877-2013.
in the COL18A1 gen associated with knobloch syndrome doi: 10.1152/physrev.00018.2018
and structural brain anomalies: A novel case report and
literature review of neuroimaging findings. Neurocase. 83. Vincent AJ, Gasperini R, Foa L, Small DH. Astrocytes in
2022;28(1):11-18. Alzheimer’s disease: Emerging roles in calcium dysregulation
and synaptic plasticity. J Alzheimers Dis. 2010;22(3):699-714.
doi: 10.1080/13554794.2021.1928228
doi: 10.3233/JAD-2010-101089
73. Liu I, Uversky VN, Munishkina LA, Fink AL, Halfter W,
Cole GJ. Agrin binds alpha-synuclein and modulates alpha- 84. Melrose J, Smith MM. Natural and Semi-synthetic
synuclein fibrillation. Glycobiology. 2005;15(12):1320-1331. flavonoid anti-SARS-CoV-2 agents for the treatment of
long COVID-19 disease and neurodegenerative disorders of
doi: 10.1093/glycob/cwj014 cognitive decline. Front Biosci (Elite Ed). 2022;14(4):27.
74. Miller J, Cummings J, Maresh GA, et al. Localization of doi: 10.31083/j.fbe1404027
perlecan (or a perlecan-related macromolecule) to isolated
microglia in vitro and to microglia/macrophages following 85. Li HL, Zhang SY, Ren YS, et al. Identification of ellagic
infusion of beta-amyloid protein into rodent hippocampus. acid and urolithins as natural inhibitors of Aβ 25-35 -induced
Glia. 1997;21(2):228-243. neurotoxicity and the mechanism predication using network
pharmacology analysis and molecular docking. Front Nutr.
doi: 10.1002/(sici)1098-1136(199710)21:2<228:aid-glia6>3.0.co;2-2 2022;9:966276.
75. Wu B, McDonald AJ, Markham K, et al. The N-terminus doi: 10.3389/fnut.2022.966276
of the prion protein is a toxic effector regulated by the 86. Kaufman AC, Salazar SV, Haas LT, et al. Fyn inhibition
C-terminus. Elife. 2017;6:e23473.
rescues established memory and synapse loss in Alzheimer
doi: 10.7554/eLife.23473 mice. Ann Neurol. 2015;77(6):953-971.
76. Jouanne M, Rault S, Voisin-Chiret AS. Tau protein doi: 10.1002/ana.24394

Volume 3 Issue 3 (2024) 16 doi: 10.36922/an.3812